» Articles » PMID: 19773635

GB Virus Type C Infection Modulates T-cell Activation Independently of HIV-1 Viral Load

Overview
Journal AIDS
Date 2009 Sep 24
PMID 19773635
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Many clinical studies have suggested a beneficial effect of GB virus type C (GBV-C) on the course of HIV-1 infection, but the mechanisms involved in such amelioration are not clear. As recent evidence has implicated cellular activation in HIV-1 pathogenesis, we investigated the effect of GBV-C viremia on T-cell activation in early HIV-1 infection.

Methods: Forty-eight recently infected HIV-1 patients (23 GBV-C viremic) were evaluated for T-cell counts, expanded immunophenotyping GBV-C RNA detection, and HIV-1 viral load. Nonparametric univariate and multivariate analyses were carried out to identify variables associated with cellular activation, including GBV-C status, HIV-1 viral load, T lymphocyte counts, and CD38 and chemokine (C-C motif) receptor 5 (CCR5) surface expression.

Finding: We not only confirmed the positive correlation between HIV-1 viral load and the percentage of T cells positive for CD38(+)CD8(+) but also observed that GBV-C viremic patients had a lower percentage of T cells positive for CD38(+)CD4(+), CD38(+)CD8(+), CCR5(+)CD4(+), and CCR5(+)CD8(+) compared with HIV-1-infected patients who were not GBV-C viremic. In regression models, GBV-C RNA(+) status was associated with a reduction in the CD38 on CD4(+) or CD8(+) T cells and CCR5(+) on CD8(+) T cells, independent of the HIV-1 viral load or CD4(+) and CD8(+) T-cell counts. These results were also supported by the lower expression of CD69 and CD25 in GBV-C viremic patients.

Interpretation: The association between GBV-C replication and lower T-cell activation may be a key mechanism involved in the protection conferred by this virus against HIV-1 disease progression to immunodeficiency in HIV-1-infected patients.

Citing Articles

Short-term antiretroviral therapy may not correct the dysregulations of plasma virome and cytokines induced by HIV-1 infection.

Ma Y, Zhang M, Wang Z, Cao L, Li Y, Wan Z Virulence. 2025; 16(1):2467168.

PMID: 39950859 PMC: 11866967. DOI: 10.1080/21505594.2025.2467168.


Co-Infections and Superinfections between HIV-1 and Other Human Viruses at the Cellular Level.

Acchioni C, Sandini S, Acchioni M, Sgarbanti M Pathogens. 2024; 13(5).

PMID: 38787201 PMC: 11124504. DOI: 10.3390/pathogens13050349.


Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease?.

Stapleton J Front Immunol. 2022; 13:887760.

PMID: 35707535 PMC: 9190258. DOI: 10.3389/fimmu.2022.887760.


Clinical and molecular aspects of human pegiviruses in the interaction host and infectious agent.

Samadi M, Salimi V, Haghshenas M, Miri S, Mohebbi S, Ghaemi A Virol J. 2022; 19(1):41.

PMID: 35264187 PMC: 8905790. DOI: 10.1186/s12985-022-01769-3.


Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication.

Yu Y, Wan Z, Wang J, Yang X, Zhang C Virulence. 2022; 13(1):324-341.

PMID: 35132924 PMC: 8837232. DOI: 10.1080/21505594.2022.2029328.